At Vaccinogen, we believe cancer must be treated while still curable, before invisible residual disease becomes metastatic and irreversible. In colon cancer, recurrence does not have to be inevitable; it is a preventable failure of timing and biology. Up to one-third of Stage II patients relapse within a few years after surgery because of microscopic tumor cells that are genetically diverse and immunologically silent, evading detection and destroying the opportunity for cure.
OncoVAX® transforms that window. By combining the patient’s own tumor with a brief immune-priming step, OncoVAX® recruits and educates the immune system to recognize and eliminate these hidden cells before they can seed recurrence in the liver, lungs, or peritoneum.
This radically simple approach is not incremental therapy; it is a fundamental redefinition of cancer care: from reactive and toxic treatments of metastasis to proactive prevention of disease. The result is survival, lower healthcare costs, and restored dignity for patients worldwide.
— Michael G. Hanna Jr., PhD
Founder, Chairman & Chief Scientific Officer, Vaccinogen Inc.